Donald Trump recently announced that he plans to implement 25% tariffs on all imports from Mexico and Canada unless these countries control the flow of illegal drugs—especially fentanyl—and illegal immigration.
A tariff-first approach to addressing these issues undermines the key role of trade and investment across North America underpinned by the United States-Mexico-Canada Agreement, writes Joshua P. Meltzer.
In a new collection of essays and policy recommendations, experts take a deep dive on the dynamics of U.S. drug markets, how to improve health outcomes, the impact of fentanyl on vulnerable communities, and much more.
The Brookings Institution is a nonprofit organization based in Washington, D.C. Our mission is to conduct in-depth, nonpartisan research to improve policy and governance at local, national, and global levels. If you were forwarded this email, sign up for the Brookings Brief to stay updated on our latest work.
The Brookings Institution,1775 Massachusetts Ave NW, Washington, DC 20036
The conclusions and recommendations of any Brookings publication are solely those of its author(s), and do not reflect the views of the Institution, its management, or its other scholars.
